Amminger, G. P., Nelson, B., Markulev, C., Yuen, H. P., Schäfer, M. R., Berger, M., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I. B., Berger, G. E., Chen, E. Y. H., de Haan, L., Nieman, D. H., Nordentoft, M., Riecher-Rössler, A., Verma, S., Thompson, A., Yung, A. R., McGorry, P. D. (2020). The NEURAPRO biomarker analysis: Long-chain omega-3 fatty acids improve 6-month and 12-month outcomes in youths at ultra-high risk for psychosis. Biological Psychiatry, 87(3), 243–252. https://doi.org/10.1016/j.biopsych.2019.08.030
Google Scholar Amminger, G. P., Schaefer, M. R., Papageorgiou, K., Becker, J., Mossaheb, N., Harrigan, S. M., McGorry, P., Berger, G. (2007). Omega-3 fatty acids reduce the risk of early transition to psychosis in ultra-high risk individuals: A double-blind randomized, placebo-controlled treatment study. Schizophrenia Bulletin, 3(suppl), 418–419.
Google Scholar Amminger, G. P., Schafer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., Berger, G. E. (2010). Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Archives of General Psychiatry, 67(2), 146–154. https://doi.org/10.1001/archgenpsychiatry.2009.192
Google Scholar Amminger, G. P., Schäfer, M. R., Schlögelhofer, M., Klier, C. M., McGorry, P. D. (2015). Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nature Communications, 11(6), 7934. https://doi.org/10.1038/ncomms8934
Google Scholar Andreasen, N. C., Nopoulos, P., Magnotta, V., Pierson, R., Ziebell, S., Ho, B. C. (2011). Progressive brain change in schizophrenia: A prospective longitudinal study of first-episode schizophrenia. Biological Psychiatry, 70(7), 672–679. https://doi.org/10.1016/j.biopsych.2011.05.017
Google Scholar Arvindakshan, M., Sitasawad, S., Debsikdar, V., Ghate, M., Evans, D., Horrobin, D. F., Bennett, C., Ranjekar, P. K., Mahadik, S. P. (2003). Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry, 53, 56–64. https://doi.org/10.1016/S0006-3223(02)01443-9
Google Scholar Bentsen, H., Landrø, N. I. (2018). Neurocognitive effects of an omega-3 fatty acid and vitamins E+C in schizophrenia: A randomised controlled trial. Prostaglandins, Leukotrienes & Essential Fatty Acids, 136, 57–66. https://doi.org/10.1016/j.plefa.2017.10.002
Google Scholar Bentsen, H., Osnes, K., Refsum, H., Solberg, D. K., Bohmer, T. (2013). A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Translational Psychiatry, 3, e335. https://doi.org/10.1038/tp.2013.110
Google Scholar Bentsen, H., Solberg, D. K., Refsum, H., Bohmer, T. (2012). Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells. Prostaglandins, Leukotrienes & Essential Fatty Acids, 87, 35–41. https://doi.org/10.1016/j.plefa.2012.05.005
Google Scholar Berger, G. E., Proffitt, T., McConchie, M., Yuen, H., Wood, S. J., Amminger, G. P., Brewer, W., McGorry, P. D. (2007). Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial. The Journal of Clinical Psychiatry, 68(12), 1867–1875. https://doi.org/10.4088/jcp.v68n1206
Google Scholar Berger, G. E., Wood, S. J., Wellard, R. M., Proffitt, T. M., McConchie, M., Amminger, G. P., Jackson, G. D., Velakoulis, D., Pantelis, C., McGorry, P. D. (2008). Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology, 33(10), 2467–2473. https://doi.org/10.1038/sj.npp.1301628
Google Scholar Borovcanin, M., Jovanovic, I., Radosavljevic, G. (2013). Antipsychotics can modulate the cytokine profile in schizophrenia: Attenuation of the type-2 inflammatory response. Schizophrenia Research, 147(1), 103–109. https://doi.org/10.1016/j.schres.2013.03.027
Google Scholar Cadenhead, K., Addington, J., Cannon, T., Cornblatt, B., Mathalon, D., McGlashan, T., Perkins, D., Seidman, L. J., Tsuang, M., Walker, E., Woods, S. (2017). Omega-3 fatty acid versus placebo in a clinical high-risk sample from the North American Prodrome Longitudinal Studies (NAPLS) consortium. Schizophrenia Bulletin, 43(suppl 1), S16. https://doi.org/10.1093/schbul/sbx021.042
Google Scholar Chen, A. T., Chibnall, J. T., Nasrallah, H. A. (2015). A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects. Annals of Clinical Psychiatry, 27(4), 289–296.
Google Scholar | Medline Emsley, R., Chiliza, B., Asmal, L., du Plessis, S., Phahladira, L., van Niekerk, E., van Rensburg, S. J., Harvey, B. H. (2014). A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophrenia Research, 158(1-3), 230–235. https://doi.org/10.1016/j.schres.2014.06.004
Google Scholar Emsley, R., Myburgh, C., Oosthuizen, P., Van Rensburg, S. J. (2002). Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. American Journal of Psychiatry, 159(9), 1596–1598. https://doi.org/10.1176/appi.ajp.159.9.1596
Google Scholar Emsley, R., Niehaus, D. J., Koen, L., Oosthuizen, P. P., Turner, H. J., Carey, P., van Rensburg, S. J., Maritz, J. S., Murck, H. (2006). The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial. Schizophrenia Research, 84(1), 112–120. https://doi.org/10.1016/j.schres.2006.03.023
Google Scholar Fenton, W. S., Dickerson, F., Boronow, J., Hibbeln, J. R., Knable, M. B. (2001). A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. American Journal of Psychiatry, 158(12), 2071–2074. https://doi.org/10.1176/appi.ajp.158.12.2071
Google Scholar Fusar-Poli, P., Berger, G. (2012). Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology, 32(2), 179–185. https://doi.org/10.1097/JCP.0b013e318248b7bb
Google Scholar Fusar-Poli, P., Bonoldi, I., Yung, A. R., Borgwardt, S., Kempton, M. J., Valmaggia, L., Barale, F., Caverzasi, E., McGuire, P. (2012). Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry, 69(3), 220–229. https://doi.org/10.1001/archgenpsychiatry.2011.1472
Google Scholar Howes, O. D., Kapur, S. (2009). The dopamine hypothesis of schizophrenia: Version III—The final common pathway. Schizophrenia Bulletin, 35(3), 549–562. https://doi.org/10.1093/schbul/sbp006
Google Scholar Hsu, M. C., Tung, C. Y., Chen, H. E. (2018). Omega-3 polyunsaturated fatty acid supplementation in prevention and treatment of maternal depression: Putative mechanism and recommendation. Journal of Affective Disorders, 238, 47–61. https://doi.org/10.1016/j.jad.2018.05.018
Google Scholar Jamilian, H., Solhi, H., Jamilian, M. (2014). Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Global Journal of Health Science, 6(7), 103–108. https://doi.org/10.5539/gjhs.v6n7p103
Google Scholar Manteghiy, A., Shakeri, M. T., Koohestani, L., Salari, E. (2008). Beneficial antipsychotic effects of omega-3 fatty acids add-on therapy for the pharmacological management of patients with schizophrenia. Iranian Journal of Psychiatry & Behavioral Science, 2(2), 35–40.
Google Scholar McEvoy, J., Baillie, R. A., Zhu, H., Buckley, P., Keshavan, M. S., Nasrallah, H. A., Dougherty, G. G., Yao, J. K., Kaddurah-Daouk, R. (2013). Lipidomics reveals early metabolic changes in subjects with schizophrenia: Effects of atypical antipsychotics. PLoS One, 8(7), e68717. https://doi.org/10.1371/journal.pone.0068717
Google Scholar McGorry, P. D., Nelson, B., Markulev, C., Yuen, H. P., Schäfer, M. R., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I. B., Berger, G. E., Chen, E. Y., de Haan, L., Nieman, D. H., Nordentoft, M., Riecher-Rössler, A. O., Verma, S., Thompson, A., Yung, A. R., Amminger, G. P. (2017). Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders the NEURAPRO randomized clinical trial. JAMA Psychiatry, 74(1), 19–27. https://doi.org/10.1001/jamapsychiatry.2016.2902
Google Scholar McNamara, R. K., Jandacek, R., Rider, T., Tso, P., Hahn, C. G., Richtand, N. M., Stanford, K. E. (2007). Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: Gender differences and partial normalization with antipsychotic medications. Schizophrenia Research, 91(1–3), 37–50. https://doi.org/10.1016/j.schres.2006.11.027
Google Scholar Miller, J., Drost, D. J., Jensen, E., Manchanda, R., Northcott, S., Neufeld, R. W., Menon, R., Rajakumar, N., Pavlosky, W., Densmore, M., Schaefer, B., Williamson, P. (2012). Progressive membrane phospholipid changes in first episode schizophrenia with high field magnetic resonance spectroscopy. Psychiatry Research, 201(1), 25–33. https://doi.org/10.1016/j.pscychresns.2011.06.017
Google Scholar Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097
Google Scholar Mossaheb, N., Schäfer, M. R., Schlögelhofer, M., Klier, C. M., Cotton, S. M., McGorry, P. D., Amminger, G. P. (2013). Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: When do they begin to be effective? Schizophrenia Research, 148(1-3), 163–167. https://doi.org/10.1016/j.schres.2013.05.027
Google Scholar Parikh, V., Khan, M. M., Mahadik, S. P. (2003). Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research, 37(1), 43–51. https://doi.org/10.1016/s0022-3956(02)00048-1.
Google Scholar Pawełczyk, T., Grancow-Grabka, M., Kotlicka-Antczak, M., Trafalska, E., Pawełczyk, A. (2016). A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. Journal of Psychiatric Research, 73, 34–44. https://doi.org/10.1016/j.jpsychires.2015.11.013
Google Scholar Pawełczyk, T., Grancow-Grabka, M., Trafalska, E., Szemraj, J., Pawełczyk, A. (2017). Oxidative stress reduction related to the efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial. Prostaglandins, Leukotrienes & Essential Fatty Acids, 121(1), 7–13. https://doi.org/10.1016/j.plefa.2017.05.004
Google Scholar Pawełczyk, T., Trafalska, E., Pawełczyk, A., Kotlicka-Antczak, M. (2015). Differences in omega-3 and omega-6 polyunsaturated fatty acid consumption in people at ultra-high risk of psychosis, first-episode schizophrenia, and in healthy controls. Early Intervention in Psychiatry, 11(6), 498–508. https://doi.org/10.1111/eip.1226
Google Scholar Peet, M., Brind, J., Ramchand, C. N., Shah, S., Vankar, G. K. (2001). Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research, 49(3), 243–251. https://doi.org/10.1016/S0920-9964(00)00083-9
Google Scholar Peet, M., Horrobin, D. F., & E-E Multicentre Study Group . (2002). A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research, 36(1), 7–18. https://doi.org/10.1016/S0022-3956(01)00048-6
Google Scholar Qiao, Y., Mei, Y., Han, H., Liu, F., Yang, X. M., Shao, Y., Xie, B., Long, B. (2018). Effects of Omega-3 in the treatment of violent schizophrenia patients. Schizophrenia Research, 195, 283–285. https://doi.org/10.1016/j.schres.2017.08.026
Google Scholar Richardson, A. J., Easton, T., Puri, B. K. (2000). Red cell and plasma fatty acid changes companying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. European Neuropsychopharmacology, 10(3), 189–193. https://doi.org/10.1016/S0924-977X(00)00068-7
Google Scholar Robinson, D. G., Gallego, J. A., John, M., Hanna, L. A., Zhang, J. P., Birnbaum, M. L., Greenberg, J., Naraine, M., Peters, B. D., McNamara, R. K., Malhotra, A. K., Szeszko, P. R. (2019). A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone. Schizophrenia Research, 204, 295–303. https://doi.org/10.1016/j.schres.2018.09.006
Google Scholar Samara, M. T., Nikolakopoulou, A., Salanti, G., Leucht, S. (2019). How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials. Schizophrenia Bulletin, 45(3), 639–646. https://doi.org/10.1093/schbul/sby095
Google Scholar Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G. I., Fava, M., Berk, M., Ng, C. H. (2016). Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. American Journal of Psychiatry, 173(6), 575–587. https://doi.org/10.1176/appi.ajp.2016.15091228
Google Scholar Sethom, M. M., Fares, S., Bouaziz, N., Melki, W., Jemaa, R., Feki, M., Hechmi, Z., Kaabachi, N. (2010). Polyunsaturated fatty acids deficits are associated with psychotic state in schizophrenia. Prostaglandins, Leukotrienes & Essential Fatty Acids, 83(3), 131–136. https://doi.org/10.1016/j.plefa.2010.07.001
Google Scholar Sivrioglu, E. Y., Kirli, S., Sipahioglu, D., Gursoy, B., Sarandol, E. (2007). The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31(7), 1493–1499. https://doi.org/10.1016/j.pnpbp.2007.07.004
Google Scholar Sommer, I. E., Bearden, C. E., Van Dellen, E., Breetvelt, E. J., Duijff, S. N., Maijer, K., van Amelsvoort, T., de Haan, L., Gur, R. E., Arango, C., Díaz-Caneja, C. M., Vinkers, C. H., Vorstman, J. A. (2016). Early interventions in risk groups for schizophrenia: What are we waiting for? NPJ Schizophrenia, 2, 16003. https://doi.org/10.1038/npjschz.2016.3
Google Scholar Stillwell, W., Shaikh, S. R., Zerouga, M., Siddiqui, R., Wassall, S. R. (2005). Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reproduction Nutrition Development, 45(4), 559–579. https://doi.org/10.1051/rnd:2005046
Google Scholar Su, K. P., Shen, W. W., Huang, S. Y. (2001). Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. European Neuropsychopharmacology, 11(4), 295–299. https://doi.org/10.1016/S0924-977X(01)00098-0
Google Scholar Taha, A. Y., Cheon, Y., Ma, K., Rapoport, S. I., Rao, J. S. (2013). Altered fatty acid concentrations in prefrontal cortex of schizophrenic patients. Journal of Psychiatric Research, 47(5), 636–643. https://doi.org/10.1016/j.jpsychires.2013.01.016
Google Scholar Van der Kemp, W. J., Klomp, D. W., Kahn, R. S., Luijten, P. R., Hulshoff, H. E. (2012). A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophrenia Research, 141(2-3), 153–161. https://doi.org/10.1016/j.schres.2012.08.014
Google Scholar van Rensburg, S. J., Smuts, C. M., Hon, D., Kidd, M., van der Merwe, S., Myburgh, C., Oosthuizen, P., Emsley, R. (2009). Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia. Metabolic Brain Disease, 24(4), 659–672. https://doi.org/10.1007/s11011-009-9160-7
Google Scholar Vik-Mo, A. O., Birkenaes, A. B., Fernø, J., Jonsdottir, H., Andreassen, O. A., Steen, V. M. (2008). Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. International Journal of Neuropsychopharmacology, 11(5), 679–684. https://doi.org/10.1017/S1461145708008468
Google Scholar Watari, M., Hamazaki, K., Hirata, T., Hamazaki, T., Okubo, Y. (2010). Hostility of drug-free patients with schizophrenia and n−3 polyunsaturated fatty acid levels in red blood cells. Psychiatry Research, 177(1), 22–26. https://doi.org/10.1016/j.psychres.2010.02.016
Google Scholar Wood, S. J., Cocchi, L., Proffitt, T. M., McConchie, M., Jackson, G. D., Takahashi, T., Pantelis, C., McGorry, P. D., Berger, G. E. (2010). Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study. Psychiatry Research: Neuroimaging, 182(2), 180–182. https://doi.org/10.1016/j.pscychresns.2009.12.003
Google Scholar